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Abstract Recent studies have suggested that inhibitors of
3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (statins)
can play a role in protection against vascular risk, which is
independent of cholesterol reduction. It could act by inhibiting
the synthesis of isoprenoids (farnesylpyrophosphate (FPP) and
geranylgeranylpyrophosphate (GGPP)), which are respectively
essential for membrane attachment and biological activity of
GTPases Ras and RhoA. This study demonstrates that a statin
(cerivastatin) inhibits angiogenesis. This effect was due to a
decrease in endothelial cell locomotion which was reversed by
GGPP. It was mainly related to delocalization of RhoA from cell
membrane to cytoplasm, responsible for the disorganization of
actin stress fibers. Furthermore, a decrease in MMP-2 secretion,
involved in cell invasion, was also observed. This effect is rather
due to Ras inhibition as it was reversed by FPP. This anti-
angiogenic activity could explain the beneficial effect of statins
on atherosclerosis and on cancer prevention as shown by clinical
studies. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
Key words: Anti-angiogenesis ; Migration;
HMG-CoA reductase inhibitor; Cerivastatin; RhoA; Ras
1. Introduction
Angiogenesis is characterized by the formation of new
capillaries from pre-existing vessels. This event is a prerequi-
site for both physiological and pathological processes as pre-
viously reported [1]. The poor prognosis of some diseases like
cancer has been shown to correlate with an increase in angio-
genesis. An excessive vascularization can also contribute to
other pathological phenomena such as atherosclerosis plaque
formation and chronic in£ammation [2].
Angiogenesis is a process induced by angiogenic factors.
Basic ¢broblast growth factor (bFGF) and vascular endothe-
lial growth factor (VEGF) were the two most well-recognized
angiogenic factors. Recently, monocyte-secreted cytokine on-
costatin M (OSM) was identi¢ed as another potent angiogen-
esis stimulating factor which could play a major role in the
development and complication of atherosclerosis [3]. These
factors contribute in two crucial steps of angiogenesis, i.e.
endothelial cell proliferation and migration. Besides these cy-
tokines, various serine proteases such as urokinase type plas-
minogen activator and plasmin as well as matrix metallopro-
teinases (MMPs) are also implicated in the cell migration
process [4]. Angiogenesis can be inhibited by anti-angiogenic
factors. Various anti-angiogenic factors so far identi¢ed like
angiostatin, endostatin and thrombospondin are all protein
fragments [5]. These raise the problem for pharmaceutical
production and the cost expense for long term therapeutically
administration required by anti-angiogenic therapy. Some
small anti-angiogenic molecules like marimastat exhibit con-
siderable side e¡ects in the clinical assay [6]. So, the develop-
ment of new anti-angiogenic factors appears emergent for
both anti-cancer and anti-atherosclerosis therapies.
The 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA)
reductase inhibitor, cerivastatin, is initially known to inhibit
cholesterol biosynthesis. Recent reports showed that cerivas-
tatin has pleiotropic e¡ects including the inhibition of smooth
muscle cell migration and proliferation [7]. Recently, it was
also shown that statins act on endothelial cells, as reported by
Mussoni et al., £uvastatin inhibits the synthesis of plasmino-
gen activator inhibitor (PAI-1) and induces the secretion of
tissue plasminogen activator suggesting an improvement in
the ¢brinolytic pathway [8].
In fact, the inhibition of HMG-CoA reductase by statins
leads to a decreased synthesis of cholesterol and also its pre-
cursors, which are isoprenoid products of mevalonate (MVA).
These isoprenoids, farnesylpyrophosphate (FPP) and geranyl-
geranylpyrophosphate (GGPP), provide lipophilic anchors
which are essential for membrane attachment and biological
activity of small GTP binding protein from the Ras family [9].
For exerting their role in cell signal transduction, protein Ras
and RhoA of the GTPase family must translocate from the
cytoplasm to the cell membrane. This translocation requires
FPP for Ras and GGPP for RhoA [10]. Activation of Ras is
involved in the activation of mitogen-activated protein kinase
and nuclear factor-kappa B (NF-UB) pathways [11] which can
play a pivotal role in angiogenesis [12^15]. Activated RhoA is
known to associate with cortical actin in focal contact sites at
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cell membrane ru¥es, and therefore is crucial for the organi-
zation of actin cytoskeleton and as consequence for cell loco-
motion which is of prime importance in angiogenesis [16].
Furthermore, the use of the exoenzyme, clostridium botuli-
num C3 transferase, which speci¢cally prevents the activation
of Rho GTPase, inhibits angiogenesis in vitro and in vivo [17].
Because cerivastatin inhibits FPP and GGPP biosynthesis
by inhibiting HMG-CoA reductase, we were prompted to
analyze the consequence of such inhibition on endothelial
cell migration and angiogenesis.
In this study, we demonstrate that cerivastatin inhibits the
migration of endothelial cells and the capillary tube formation
stimulated by angiogenic factors, i.e. bFGF, VEGF and
OSM. We tested OSM in addition to well-known angiogenic
factors (bFGF and VEGF) because this in£ammatory cyto-
kine is largely expressed in the atheromatous plaque. We also
assessed the molecular mechanism of such inhibition related
particularly to Ras and RhoA inhibition.
2. Materials and methods
2.1. Cytokines and cerivastatin
RpD Systems (Minneapolis, MN, USA) supplied recombinant hu-
man OSM, VEGF and bFGF. Cerivastatin was kindly provided by
Bayer-Pharma (Puteaux, France).
2.2. Cell culture
The HMEC-1 (human microvascular endothelial cell) cell line was
provided by Dr. Ades (Centers for Disease Control and Prevention,
Atlanta, GA, USA) [18]. HMEC-1 were cultured in MCDB-131 me-
dium (Sigma, St. Louis, MO, USA), supplemented with 15% fetal calf
serum (FCS), 100 IU/ml penicillin, 100 Wg/ml streptomycin, 10 ng/ml
epidermal growth factor (Euromedex, Sou¡elweyersheim, France) and
1 mg/ml hydrocortisone (Pharmacia-Upjohn, Saint Quentin en Yve-
lines, France).
2.3. Cell migration assays
2.3.1. By transwell method. HMEC-1 were detached with EDTA
0.5 mM, washed twice in phosphate-bu¡ered saline (PBS) and re-
suspended in MCDB-131 medium with 0.2 mg/ml bovine serum albu-
min (BSA, Sigma). 50U103 cells were seeded in the upper chamber of
a transwell insert (PTFE membrane with 8 Wm diameter pores, Dutch-
er, Brumath, France). The lower chamber was ¢lled with 1 ml of
MCDB-131 with 2 mg/ml of BSA without or with angiogenic factors
(bFGF, VEGF or OSM) used at indicated concentrations. In order to
test the e¡ect of HMG-CoA reductase inhibitor on cytokine-induced
chemotaxis, cerivastatin was added to the upper chamber at a ¢nal
concentration of 10 and 25 ng/ml. After 24 h, migrated cells were
scraped from the lower surface of the membrane with a cell scraper
(Nunc) and then suspended in the medium of the lower chamber to
count all migrating cells (both adherent and cells in suspension).
These cells were counted with a hemocytometer (Coulter Z1, Coul-
tronics). To address whether inhibition of isoprenoid intermediates of
cholesterol biosynthesis is involved in the cerivastatin e¡ect, experi-
ments were performed in presence of MVA (100 WM), FPP (10 WM) or
GGPP (10 WM) (Sigma).
2.3.2. By wound healing method. Endothelial cells were cultured in
24-well culture plate. When HMEC-1 were con£uent, a wound was
performed under standard conditions. Then after washing with PBS,
the cells were incubated for 24 h with MCDB-131 containing 2% FCS
(concentration of FCS which allows cell survival but not cell prolif-
eration) without or with growth factors (bFGF, VEGF or OSM) used
at indicated concentrations. All the assays were performed in the
absence or presence of cerivastatin at indicated concentrations. Ex-
periments were performed with and without MVA, FPP or GGPP as
indicated above. After a 24 h incubation, cells were washed twice with
PBS and then ¢xed in 4% paraformaldehyde in PBS for 10 min at
room temperature. The cells were then stained with Giemsa. Cells
migrated into the wound site were photographed at a magni¢cation
of 50U.
2.4. Capillary tube formation from microcarriers in three-dimensional
¢brin gel
The capillary tube formation assay was performed by the technique
of Nehls et al., slightly modi¢ed [19]. Formation of capillary tube
arising from the periphery of microcarrier beads was observed and
photographed with a camera on a reverse microscope at the 4th day
of culture.
2.5. Confocal microscopy analysis of RhoA and actin ¢laments
The confocal microscopy analysis of RhoA and actin ¢laments was
performed, according to the protocol of Menager et al. [16], on the
bFGF-stimulated HMEC-1 after an 18 h incubation with cerivastatin.
RhoA was detected using ¢rst a monoclonal antibody against RhoA
(Santa Cruz Biotechnology, CA, USA) and second a £uorescein iso-
thiocyanate (FITC)-conjugated anti-mouse IgG (Immunotech). Actin
¢laments were visualized by tetra methyl rhodamine isothiocyanate
(TRITC)-labeled phalloidin. Computer-assisted image analysis of
£uorescence was performed using a confocal microscopy scanning
laser microscope (Leica TCS, wavelength excitation 488 nm, emission
525 nm for FITC; 540/570 nm for TRITC).
2.6. MMP-2 secretion
2.6.1. By reverse transcriptase-polymerase chain reaction assay (RT-
PCR). To isolate RNA, cells were incubated in a 6-well plate
(Nunc) up to con£uence and then incubated for 6 h with or without
the cytokines and cerivastatin. Cells were then detached by a non-
enzymatic cell dissociation solution (Sigma) and washed twice in PBS.
Total RNA extraction was performed using SV total isolation system
(Promega, Madison, WI, USA) according to the manufacturer’s in-
structions.
Table 1
Inhibitory e¡ect induced by cerivastatin on OSM-, bFGF- and VEGF-stimulated HMEC-1 migration by transwell method after a 24 h incuba-
tion
Control OSM bFGF VEGF
Without cerivastatin 1 2.06 þ 0.06* 1.46 þ 0.04* 1.40 þ 0.03*
Cerivastatin 10 ng/ml 1.03 þ 0.05 1.22 þ 0.04*** 1.09 þ 0.06** 1.16 þ 0.03**
Cerivastatin 25 ng/ml 0.98 þ 0.06 0.94 þ 0.03*** 1.08 þ 0.02*** 1.05 þ 0.04***
MVA 1 1.95 þ 0.06* n.d. n.d.
Cerivastatin 10 ng/ml+MVA 1.01 þ 0.06 1.92 þ 0.03* n.d. n.d.
Cerivastatin 25 ng/ml+MVA 1.05 þ 0.05 1.89 þ 0.05* n.d. n.d.
FPP 1 2.03 þ 0.08* n.d. n.d.
Cerivastatin 10 ng/ml+FPP 1.02 þ 0.06 1.34 þ 0.05*** n.d. n.d.
Cerivastatin 25 ng/ml+FPP 1.03 þ 0.03 1.08 þ 0.04*** n.d. n.d.
GGPP 1 1.97 þ 0.08* 1.46 þ 0.04* 1.36 þ 0.04*
Cerivastatin 10 ng/ml+GGPP 1.12 þ 0.03 1.88 þ 0.08* 1.56 þ 0.07* 1.30 þ 0.06*
Cerivastatin 25 ng/ml+GGPP 0.97 þ 0.04 1.94 þ 0.04* 1.37 þ 0.05* 1.33 þ 0.05*
E¡ect of MVA, FPP and GGPP on cerivastatin-induced inhibition of endothelial cell migration.
Results of four experiments in duplicate are expressed as the ratio of the number of migrated cells over the number of migrated cells in each
control þ S.E.M. (*P6 0.001 as compared with cerivastatin-untreated cells, **P6 0.05; ***P6 0.001 as compared with OSM-, bFGF- or
VEGF-treated cells, n = 4). MVA = 100 WM; GGPP = 10 WM; FPP = 10 WM (n.d., not determined).
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For RT-PCR, oligonucleotide primers were chosen using a biomo-
lecular sequence databases (GenBank) and were synthesized by Gen-
set (Paris, France). The sequences of MMP-2 sense primer (5P-
GGCCCTGTCACTCCTGAGAT-3P) and MMP-2 anti-sense primer
(5P-GGCATCCAGGTTATCGGGGA-3P) or L-actin sense primer (5P-
ATCTGGCACCACACCTTCTACAATGAGCTGCG-3P) and L-ac-
tin anti-sense primer (5P-CGTCATACTCCTGCTTGCTGATCCAC-
ATCTGC-3P) were used in a RT-PCR assay. RT-PCRs were per-
formed in the same condition as described previously [20]. The
MMP-2 and the L-actin mRNA ampli¢cation product were size-frac-
tionated through a 1.5% agarose gel electrophoresis using ethidium
bromide staining.
2.6.2. By sodium dodecyl phosphate (SDS)^polyacrylamide gel elec-
trophoresis zymography for MMP assay. The supernatants of
HMEC-1 incubated for 24 h, in the absence or in the presence of
cerivastatin with or without MVA, FPP or GGPP, were collected.
Fig. 1. Inhibitory e¡ect induced by cerivastatin on OSM- and bFGF-stimulated HMEC-1 migration by wound healing method after a 24 h in-
cubation. E¡ect of MVA, FPP and GGPP on cerivastatin-induced inhibition of endothelial cell migration. Column A: unstimulated cells, col-
umn B: OSM 2.5 ng/ml, column C: bFGF 25 ng/ml. Line 1: control, line 2: cerivastatin 25 ng/ml, line 3: MVA 100 WM, line 4: MVA 100
WM+cerivastatin 25 ng/ml, line 5: FPP 10 WM, line 6: FPP 10 WM+cerivastatin 25 ng/ml, line 7: GGPP 10 WM, line 8: GGPP 10 WM+cerivas-
tatin 25 ng/ml.
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Fig. 2. Inhibitory e¡ect induced by cerivastatin on OSM-, bFGF- and VEGF-stimulated capillary tube formation in a three-dimensional ¢brin
gel. E¡ect of MVA, FPP and GGPP on cerivastatin-induced inhibition of capillary tube formation. Column A: unstimulated cells, column B:
OSM 2.5 ng/ml, column C: bFGF 25 ng/ml, column D: VEGF 20 ng/ml. Line 1: control, line 2: cerivastatin 10 ng/ml, line 3: cerivastatin 25
ng/ml, line 4: MVA 100 WM+cerivastatin 25 ng/ml, line 5: FPP 10 WM+cerivastatin 25 ng/ml, line 6: GGPP 10 WM+cerivastatin 25 ng/ml
(scale bar = 150 Wm).
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Then, 10 Wl of each supernatant were loaded on a 7.5% polyacryl-
amide gel containing 10% SDS and 1 mg/ml gelatin under non-reduc-
ing conditions and then subjected to electrophoresis. Gels were then
washed in 2.5% Triton X-100 for 1 h at room temperature in order to
remove SDS. Gelatinase activity was revealed by its gelatinolic activ-
ity after an overnight incubation at 37‡C in fresh developing bu¡er
containing 50 mM Tris^HCl, 5 mM CaCl2, pH 7.6. The gel was then
stained with Coomassie brilliant blue R-250 solution (0.25%). Gelat-
inolic activity was evidenced as clear bands against the blue back-
ground of stained gelatin.
2.7. Statistical analysis
Signi¢cant values were determined using a two-tailed non-paramet-
ric Mann^Whitney test using the InStat software (Sigma). The results
are expressed as mean value þ standard error of the mean (S.E.M.).
P6 0.05 was considered as signi¢cant.
3. Results and discussion
Cerivastatin has been demonstrated to inhibit both migra-
tion and proliferation of smooth muscle cells [7]. However, its
e¡ect on microvascular endothelial cells has not yet been ex-
plored. In this work, we demonstrated that cerivastatin in-
duced a dose-dependent decrease in endothelial cell migration
in two di¡erent models.
3.1. Cerivastatin inhibited the endothelial cell migration in a
transwell system
Cerivastatin (10 and 25 ng/ml) induced a signi¢cant inhibi-
tion of OSM-, bFGF- and VEGF-stimulated endothelial cell
Fig. 3. E¡ect of cerivastatin on localization of RhoA and on actin stress ¢bers after a 18 h incubation. Panels 1A,B: bFGF 25 ng/ml, panels
2A,B: cerivastatin 10 ng/ml+bFGF 25 ng/ml, panels 3A,B: cerivastatin 25 ng/ml+bFGF 25 ng/ml.
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migration from the upper chamber to the lower one through
the membrane (Table 1). Moreover, the inhibitory e¡ect of
cerivastatin on HMEC-1 cell migration was fully reversible
by co-incubation with MVA or GGPP but not with FPP
(Table 1). Cerivastatin did not inhibit the migration of un-
stimulated endothelial cells, suggesting that cerivastatin has
only an inhibitory e¡ect on endothelial cells activated by an-
giogenic factors. This result indicates that cerivastatin could
suppress the angiogenic factors-stimulated cell locomotion in
responding to chemotaxis agents. Moreover, cerivastatin did
not induce any toxic e¡ect as shown by the absence of trypan
blue incorporation into the cells. These results indicate that
cerivastatin could suppress the angiogenic factors-stimulated
cell locomotion in responding to chemotaxis agents and this
e¡ect is mainly related to the inhibition of GGPP synthesis.
3.2. Cerivastatin inhibited the endothelial cell migration in
wound healing assay
In the wound healing assay, cerivastatin (25 ng/ml) inhib-
ited cell migration in both stimulated (Fig. 1, panels 2B,C) or
unstimulated (Fig. 1, panel 2A) endothelial cells in a dose-
dependent manner (data not shown for 10 ng/ml of cerivas-
tatin). Co-treatment of cerivastatin with MVA (Fig. 1, panels
4A^C) or GGPP (Fig. 1, panels 8A^C) reversed this inhibitory
e¡ect while FPP did not (Fig. 1, panels 6A^C). Similar results
were demonstrated on VEGF-stimulated cells (data not
shown). These results con¢rm that the inhibition of cell mi-
gration induced by cerivastatin is mainly due to the inhibition
of GGPP synthesis.
3.3. Cerivastatin inhibited the capillary tube formation
After 4 days of culture in ¢brin matrix, the formation of
tube like structure was observed under phase contrast micros-
copy. When cerivastatin was added to the ¢brin matrix, a low
dose of this drug (10 ng/ml) was su⁄cient to abolish the tube
formation in the absence or in the presence of angiogenic
factors (Fig. 2, panels 2A^D). MVA and GGPP reversed
the inhibitory e¡ect of cerivastatin (25 ng/ml) on capillary
tube formation (Fig. 2, panels 4A^D and 6A^D, respectively).
FPP also reversed the e¡ect of cerivastatin but only partially
(Fig. 2, panels 5A^D). Same reversions were observed in pres-
ence of 10 ng/ml of cerivastatin (data not shown). Control
done without cerivastatin showed that MVA, FPP and
GGPP alone did not modify the capillary tube formation
(data not shown).
This observation showing that GGPP elicited a greater re-
version of cerivastatin e¡ect than FPP, indicates that the in-
hibitory e¡ect of cerivastatin on angiogenesis is mainly due to
the inhibition of GGPP synthesis, as already noted for cell
migration.
3.4. Cerivastatin induced a delocalization of RhoA from cell
membrane and actin depolymerization
As indicated above, all results indicate that the e¡ect of
cerivastatin is related to the inhibition of isoprenoids biosyn-
thesis and mostly GGPP. Therefore, as geranylation of RhoA
is implicated in cell membrane translocation and cell locomo-
tion, we investigated the RhoA distribution on bFGF-stimu-
lated endothelial cells. Confocal microscopy assay was per-
formed to localize RhoA in the cell compartment. In
absence of cerivastatin, RhoA was present at the membrane
periphery and at the lamellipodia extensions and occurred in
stress ¢bers (Fig. 3, panel A1). After a 18 h treatment with 10
ng/ml of cerivastatin, RhoA remained largely di¡used in the
cytoplasm mainly in the perinuclear region (Fig. 3, panel A2).
Parallel to the delocalization of RhoA from cell membrane,
cerivastatin completely inhibited the formation of actin ¢la-
ments (Fig. 3, panel 2B). Neither organized actin ¢laments
nor focal adhesion points were detected after a 18 h treatment
with 25 ng/ml cerivastatin (Fig. 3, panels 3A,B). As shown on
Table 2, the study of the £uorescence pro¢le evaluated on cell
membrane showed that cerivastatin dose-dependently and sig-
ni¢cantly decreased cell membrane-associated RhoA and ac-
tin. It was checked that in the absence of the ¢rst antibody, no
£uorescence was detected as control (data not shown).
Therefore, we have demonstrated that cerivastatin induced
a delocalization of RhoA from cell membrane to the cyto-
plasm and this e¡ect led to the disruption of skeleton actin
stress ¢bers. This was associated with cell rounding. As the
RhoA GTPases have been shown to play a key role on cell
migration and invasion [21], the inhibition of endothelial cell
migration and tube formation induced by cerivastatin could
be due to the inhibition of RhoA translocation from cyto-
plasm to the cell membrane.
3.5. Cerivastatin decreased the secretion of MMP-2
Zymography showed that after a 24 h incubation with cer-
ivastatin, the band corresponding to MMP-2 (molecular
weight 72 000 Da) was dose-dependently reduced. The activity
of this MMP was remarkably inhibited from 10 ng/ml of
cerivastatin (Fig. 4A, lane 3). At 25 ng/ml of cerivastatin,
MMP-2 activity was completely inhibited (Fig. 4A, lane 4).
Parallel to the decrease of MMP-2 activity, RT-PCR assay
revealed that incubation of endothelial cells for 6 h with
cerivastatin induced a 50% decrease of mRNA intensity at
10 ng/ml (Fig. 4B, lane 3) and 62% decrease at 25 ng/ml
(Fig. 4B, lane 4).
Co-incubation of endothelial cells with cerivastatin (25
ng/ml) and either MVA or FPP reversed the cerivastatin-in-
duced inhibition of MMP-2 activity as shown by zymography
analysis (Fig. 4D, lane 4 for MVA, lane 6 for FPP) while
GGPP did not (Fig. 4D, lane 8). Therefore, the dose-depen-
dent inhibition of MMP-2 secretion induced by cerivastatin
on endothelial cells could be related to the inhibition of the
Ras pathway secondary to the inhibition of FPP formation.
In fact, it has been recently demonstrated that LPS-activated
MMP-2 expression on endothelial cells was mediated through
Table 2
E¡ect of a 18 h incubation with cerivastatin on the £uorescence
pro¢le of RhoA and actin associated to cell membrane of endothe-
lial cells
RhoA Actin
Mean S.E.M. Mean S.E.M.
Control 126.82 13.8 254.55 3.49
Cerivastatin 10 ng/ml 83.65 7.9* 126.35 7.75***
Cerivastatin 25 ng/ml 31.26 5.17** 51.69 6.61***
bFGF-stimulated HMEC-1 were incubated for 18 h with cerivasta-
tin at indicated concentrations. Fluorescence pro¢le of RhoA and
actin associated to cell membrane was then performed by the com-
puter-assisted image analysis of the confocal microscope. Results are
expressed as the mean of £uorescence (arbitrary £uorescence uni-
ty) þ S.E.M. (*P6 0.05; **P6 0.001 for RhoA as compared with
cerivastatin-untreated cells, ***P6 0.001 for actin as compared with
cerivastatin-untreated cells, n = 4).
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an NF-UB pathway [22], which was activated by the trans-
location of Ras [11].
All these results demonstrate that cerivastatin, an inhibitor
of HMG-CoA reductase, induces an inhibition of angiogene-
sis. This inhibition could explain, at least in part, the protec-
tive e¡ect of the drug against atherothrombotic events which
were higher than that expected by the cholesterol decrease.
Indeed, angiogenesis is involved in plaque progression and
fragilization leading to plaque rupture and adverse clinical
outcome due to occlusive thrombi formation.
Our results are in contrast with the recently published data
of Kureishi et al. [23], which reported that statins promote
angiogenesis, a phenomenon attributed to Akt activation. The
protein kinase Akt, a downstream e¡ector of the PI-3 kinase,
has been clearly demonstrated to promote angiogenesis by
inducing actin reorganization and membrane ru¥ing [24^
26]. The conclusion of Kureishi et al. [23] does not match
our observations which show that cerivastatin strongly inhib-
its actin stress ¢bers organization and consequently endothe-
lial cell migration. In addition, as Akt could be activated
through Ras activation (an upstream activator of PI-3 kinase),
this Akt pathway is not thought to be activated by statins
treatment because of their inhibiting e¡ect on Ras and
RhoA activation [27].
This discrepancy could be due to the di¡erence of the en-
dothelial cell origin as we used microcapillary endothelial cells
whereas these authors used human umbilical vascular endo-
thelial cells or bovine aortic endothelial cells both representa-
tives of macrovasculature. The anti-angiogenic e¡ect of ceri-
vastatin described in this study was also con¢rmed using
another endothelial cell from microvasculature of bone mar-
row origin (human bone marrow endothelial cell ; results not
shown).
In conclusion, in our experimental conditions, cerivastatin
strongly inhibits endothelial cell locomotion and capillary
tube formation, indicating that cerivastatin could be consid-
ered as an anti-angiogenic substance. Its inhibitory e¡ect was
reversed by MVA and GGPP indicating that it was related to
the inhibition of GGPP formation. As RhoA activation is
dependent on geranylgeranylation, we suggest that the inhib-
itory e¡ect of cerivastatin on endothelial cell migration is
mainly related to the inhibition of RhoA activation. This is
in good accordance with the cerivastatin-induced transloca-
tion of RhoA from cell membrane to the cytoplasm. In addi-
tion, FPP partially reversed the anti-angiogenic activity of
cerivastatin, probably by reversing the inhibition of MMP-2
secretion.
Currently, statins are among the most commonly prescribed
drugs in patients with vascular risk. Our results suggest that
anti-angiogenic e¡ects of statins should be considered for in-
hibiting atherosclerosis as expected but might also inhibit tu-
mor progression. This has been supported by clinical studies
which have demonstrated that statin treatment reduced the
incidence of cancers [28].
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